Chest ACCP Career Connection
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ardizzoni, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ardizzoni, A.
(Chest. 1996;109:83S-86S.)
© 1996 American College of Chest Physicians

Efficient Designs for Testing New Agents and Regimens

Andrea Ardizzoni MD1

1 From the Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy

Current clinical chemotherapy trial procedures in non-small cell lung cancer (NSCLC) require large numbers of patients and last up to 10 years before providing results that are often disappointing. Different designs are available that offer the advantages of smaller numbers of patients, shorter duration, and earlier identification of ineffective or highly active agents and regimens. An alternative method is proposed, combining phase II screening, randomized phase II studies, and multicenter, comparative, randomized phase III trials. Issues under discussion include the combined study in phase II of different disease stages and the need for recruitment to larger trials.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American College of Chest Physicians.